AI Verdict
Both stocks have similar AI ratings. Review detailed metrics below.
IMRX vs IMKTA Fundamental Comparison
| Metric | IMRX | IMKTA |
|---|---|---|
| Revenue | $0.0 | $1.4B |
| Net Income | $-56.0M | $28.1M |
| Net Margin | N/A | 2.0% |
| ROE | -25.6% | 1.7% |
| ROA | -24.2% | 1.1% |
| Current Ratio | 17.50x | 3.36x |
| Debt/Equity | 0.00x | 0.30x |
| EPS | $-1.27 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IMRX vs IMKTA: Frequently Asked Questions
Is IMRX or IMKTA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), both stocks have similar ratings. IMRX is rated SELL (72% confidence) while IMKTA is rated SELL (72% confidence). This is not investment advice.
How does IMRX compare to IMKTA fundamentally?
Immuneering Corp has ROE of -25.6% vs INGLES MARKETS INC's 1.7%. Net margins are N/A vs 2.0% respectively.
Which stock pays higher dividends, IMRX or IMKTA?
IMRX has a dividend yield of N/A or no dividend while IMKTA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IMRX or IMKTA for long term?
For long-term investing, consider that IMRX has SELL rating with 72% confidence, while IMKTA has SELL rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IMRX vs IMKTA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IMRX vs IMKTA, both AIs rate them similarly based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.